LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
VIVS
VivoSim Labs, Inc.
There isn't enough reported data to score VIVS yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VIVS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
VIVS's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VIVS PE Valuation
VIVS has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
VIVS Forward outlook
There aren't enough analyst estimates for VIVS to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over VIVS on earnings quality, reporting a profit while its opponent remains loss making.
VIVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.51 | -666% |
| Q2 2026 | -$4.46 | -$4.38 |
| Q1 2026 | -$5.35 | -$3.65 |
| Q4 2025 | $1.87 | +$11.95 |
| Q3 2025 | $0.62 | +$13.22 |
| Q2 2025 | -$0.08 | +$16.36 |
| Q1 2025 | -$1.70 | +$17.50 |
| Q4 2024 | -$10.08 | +$16.08 |
VIVS has swung to a loss: it lost $3.51 per share over the past year, after a profit the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over VIVS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over VIVS on profitability, with a higher operating margin.
VIVS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $51K | +82% |
| Q2 2026 | $18K | -51% |
| Q1 2026 | $40K | -22% |
| Q4 2025 | $26K | +8.3% |
| Q3 2025 | $28K | -6.7% |
| Q2 2025 | $37K | -5.1% |
| Q1 2025 | $51K | +76% |
| Q4 2024 | $24K | +380% |
VIVS's revenue is recovering but still below its 2019 peak: $51,000 last quarter, up 82% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6502% | +2909 points |
| Q2 2026 | -15328% | -7449 points |
| Q1 2026 | -7968% | -1783 points |
| Q4 2025 | -10577% | +3873 points |
| Q3 2025 | -9411% | -717 points |
| Q2 2025 | -7878% | +804 points |
| Q1 2025 | -6184% | +4492 points |
| Q4 2024 | -14450% | +59150 points |
VIVS's operating margin was −6502% last quarter, up 2909 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with VIVS at up 15%.
VIVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.2M | +$704K |
| Q1 2026 | -$2.2M | -$203K |
| Q4 2025 | -$2.3M | -$470K |
| Q2 2025 | -$3.9M | -$957K |
| Q1 2025 | -$2M | +$636K |
| Q4 2024 | -$1.8M | +$1.7M |
| Q3 2024 | -$2.7M | +$521K |
| Q2 2024 | -$3M | +$2.3M |
VIVS has burned cash in almost every quarter: −$10M over the past year, against −$10M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VIVS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VIVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +214% | +11.2M shares |
| 1 year | +557% | +13.9M shares |
| 3 years | +2165% | +15.7M shares |
| 5 years | +2777% | +15.9M shares |
| Available history | +2925% | +15.9M shares |
VIVS has 16M diluted shares, up 557% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | — |
| Q4 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VIVS Net Leverage
VIVS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VIVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.5 | Oversold |
| Stochastic | 3.0 | Oversold |
VIVS's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VIVS PE vs Healthcare Sector
| Metric | VIVS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VIVS has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over VIVS on trend strength, trading above more of its moving averages.
VIVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 18% below |
| 20 week MA | $0.33 | 58% below |
| 50 week MA | $1.18 | 88% below |
| 100 week MA | $1.95 | 93% below |
| 200 week MA | $8.06 | 98% below |
VIVS is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over VIVS on returns for 2026, with the stronger performance.
VIVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $96.0 | $191.5 | +100% |
| 2021 | $191.5 | $48.2 | -75% |
| 2022 | $48.2 | $19.1 | -60% |
| 2023 | $19.1 | $13.3 | -30% |
| 2024 | $13.3 | $3.67 | -72% |
| 2025 | $3.67 | $2.01 | -45% |
| 2026 YTD | $2.01 | $0.14 | -93% |
VIVS has finished five years in a row lower, and it's down 93% so far in 2026.